The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

arrowheadpharma.com

Founded Year

1989

Stage

PIPE - II | IPO

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Arrowhead Pharmaceuticals Headquarter Location

177 East Colorado Boulevard Suite 700

Pasadena, California, 91105,

United States

626-304-3400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Arrowhead Pharmaceuticals Patents

Arrowhead Pharmaceuticals has filed 127 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Molecular biology
  • RNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/31/2019

7/12/2022

Dosage forms, Drug delivery devices, Hepatology, Molecular biology, Diseases of liver

Grant

Application Date

5/31/2019

Grant Date

7/12/2022

Title

Related Topics

Dosage forms, Drug delivery devices, Hepatology, Molecular biology, Diseases of liver

Status

Grant

Latest Arrowhead Pharmaceuticals News

NASH ‘fastest growing cause’ of liver cancer death worldwide

Aug 11, 2022

Disclosures: Loomba reports serving as a consultant for 89 Bio, Aardvark Therapeutics, Altimmune, Amgen, Anylam/Regeneron, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse Bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Merck, Metacrine Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet, Theratechnologies, Terns Pharmaceuticals and Viking Therapeutics; and is co-founder of LipoNexus Inc. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Despite global declines in liver cancer mortality attributed to hepatitis B and C, liver cancer mortality rose sharply in the Americas, driven by an increase in nonalcoholic steatohepatitis, according to data publishing in Cell Metabolism. “NASH is the fastest growing cause of hepatocellular carcinoma in the Americas and the fastest growing cause of age-adjusted liver cancer deaths globally,” study co-author Rohit Loomba, MD, MHSc, professor of medicine, director of hepatology and the NAFLD Research Center, and vice chief of gastroenterology at the University of California, San Diego, told Healio. “Urgent measures are required at a global level to tackle the underlying metabolic risk factors and slow the growing burden of NASH-related liver cancer.” Source: Adobe Stock Using data from the 2019 Global Burden of Disease study, Loomba and colleagues estimated trends in the burden of liver cancer and contributions of liver disease etiologies in 204 countries and territories from 2010 to 2019. They identified 484,577 deaths worldwide due to liver cancer in 2019 compared with 386,342 deaths in 2010. Although researchers reported a 25% increase in liver cancer deaths and a 27% increase in liver cancer cases during this period, they noted no significant changes in age-standardized death and incidence rates. Rohit Loomba “The growth, as well as aging, of the world population may contribute to the observed disconnect in the temporal trends of frequency and age-standardized incidence and death rates,” researchers wrote. In addition, age-standardized death rates (ASDRs) from liver cancer increased only in the Americas from 2012 to 2019 (annual percent change [APC] = 1.09%; 95% CI, 0.97-1.22). Globally, NASH was the fastest growing cause of age-adjusted liver cancer deaths (APC = 0.70%; 95% CI, 0.43-0.97) during the study period, followed by alcohol (APC = 0.23%; 95% CI, 0.09-0.37). The highest increase in alcohol-associated liver cancer was reported in the Americas (APC = 1.78%; 95% CI, 1.64-1.93). “The global alcohol-per-capita consumption is projected to rise further, especially in the Western Pacific and Southeast Asia,” Loomba said. “Implementing policies such as an increased price and taxation for alcohol may be considered at a national level to reduce the burden of alcohol-associated liver cancer in countries with a high alcohol-per-capita consumption.” Despite global increases in NASH - and alcohol-associated liver cancer deaths, investigators reported that ASDRs of liver cancer due to hepatitis B (APC = –0.20%; 95% CI, – 0.31 to – 0.09) and hepatitis C (APC = –0.62%; 95% CI, – 0.79 to – 0.46) declined. “The incidence of liver cancer due to NASH is projected to increase further in the next decade in the United States, Europe and Asia,” Loomba said. “We need to better understand gene-environment interaction that is driving the rise of NASH-related HCC globally, [namely] what are the causes of NAFLD-related HCC among non-cirrhotics and how can we intervene to reduce the risk of NASH-related HCC?” Read more about

Arrowhead Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Arrowhead Pharmaceuticals Rank

  • When was Arrowhead Pharmaceuticals founded?

    Arrowhead Pharmaceuticals was founded in 1989.

  • Where is Arrowhead Pharmaceuticals's headquarters?

    Arrowhead Pharmaceuticals's headquarters is located at 177 East Colorado Boulevard, Pasadena.

  • What is Arrowhead Pharmaceuticals's latest funding round?

    Arrowhead Pharmaceuticals's latest funding round is PIPE - II.

  • Who are the investors of Arrowhead Pharmaceuticals?

    Investors of Arrowhead Pharmaceuticals include Johnson & Johnson Innovation, Fidelity Investments, Clarion Capital Partners, JGD Management and Heights Capital Management.

  • Who are Arrowhead Pharmaceuticals's competitors?

    Competitors of Arrowhead Pharmaceuticals include Ionis Pharmaceuticals.

You May Also Like

Dicerna Pharmaceuticals Logo
Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.

Regulus Therapeutics Logo
Regulus Therapeutics

Regulus Therapeutics (NASDAQ: RGLS), a biopharmaceutical company, focuses on the discovery and development of drugs that target RNAs to treat a range of diseases in the United States. The Company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 to treat nonalcoholic steatohepatitis in patients with type 2 diabetes/pre-diabetes. The company has strategic alliance with GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases; Sanofi to discover and develop microRNA therapeutics for fibrotic diseases; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and Biogen to evaluate the use of microRNA signatures as a biomarker for human patients with various sclerosis.

Akcea Therapeutics Logo
Akcea Therapeutics

Akcea Therapeutics (NASDAQ: AKCA) is a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

Silence Therapeutics Logo
Silence Therapeutics

Silence Therapeutics (LON: SLN) focuses on the development of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins.

Sarepta Therapeutics Logo
Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.

Alnylam Pharmaceuticals Logo
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company believes that are many new therapeutic frontiers for its RNA technology, including applications in vaccine development, stem cell biology, bio-processing, genomics and biologics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.